Denali Therapeutics (DNLI) Stock Forecast & Price Target

Denali Therapeutics is well positioned by the accelerated FDA approval and early commercial launch of AVLAYAH, which is already treating first patients and showing a biomarker response that appears meaningfully superior to standard of care, with more than 90% of patients at goal after switching. The company also has a broadened CNS growth platform, highlighted by the first patient dosed in the Phase 1b DNL628 study and a fully enrolled DNL593 program with full biomarker data expected by year-end 2026, while Takeda’s exit leaves Denali with 100% of the commercial upside. Financially, Denali exited 1Q26 with $1.05 billion in cash and a Priority Review Voucher that could add non-dilutive funding, supporting continued pipeline advancement despite ongoing R&D investment.

Denali Therapeutics is exposed to significant regulatory risk because its reliance on accelerated review paths may not translate into approval, and regulators could demand additional data or longer studies before allowing products to advance. The company’s prospects are further constrained by the possibility that approved labels may lack important features, which would weaken commercialization potential and limit market traction for its neurodegenerative disease programs. Financially, DNLI will likely need to access the capital markets to fund ongoing development, and any inability to raise capital could delay or derail programs, underscoring a fragile funding profile.